Welcome to our dedicated page for FULLER H B CO SEC filings (Ticker: FUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on FULLER H B CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into FULLER H B CO's regulatory disclosures and financial reporting.
Fuller H B Co director Charles T. Lauber reported a compensation-related grant of 2,894.7400 Stock Units on July 15, 2026 at $57.0000 per unit. These units convert into common stock on a 1-for-1 basis upon retirement, death, disability or other specified plan events, subject to legal holding periods.
Following the grant, Lauber directly holds 13,116.4500 Stock Units and 1,351.0000 shares of common stock, including units accumulated through a dividend equivalent feature of the Directors' Deferred Compensation Plan.
FULLER H B CO director Ruth Kimmelshue reported her equity position, including a grant of 2,894.7400 stock units on 2026-07-15 at $57.0000 per unit. These stock units, now totaling 36,908.8900 units, convert into common stock on a 1-for-1 basis under a deferred compensation plan. She also holds 1,351.0000 common shares directly.
Michael J. Happe, a director of H.B. Fuller (FUL), reported a stock unit award and updated holdings. On 2026-07-15 he received 2,894.7400 Stock Units at $57.0000 per unit under a deferred compensation plan, bringing his direct stock unit balance to 17,769.0300, plus 1,343.0000 shares of common stock held directly. The units convert into common stock on a 1-for-1 basis upon retirement, death, disability or other specified events and include amounts from a dividend equivalent feature.
Thomas W. Handley, a director of HB Fuller, received a grant of 2,894.7400 Stock Units on 2026-07-15 at a reference price of $57.0000 per unit. These units convert into common stock on a 1-for-1 basis upon retirement, death, disability or other specified events under the Directors' Deferred Compensation Plan.
Following the award, Handley directly holds 81,230.4400 Stock Units, including amounts from a dividend equivalent feature, and 1,347.1000 shares of common stock. The grant is a compensation-related acquisition, not an open-market purchase or sale.
FULLER H B CO director Daniel L Florness reported a grant of 2,894.7400 Stock Units at $57.0000 per unit, each convertible into one share of common stock. These deferred units generally convert upon retirement, death, disability or certain specified events under the Directors' Deferred Compensation Plan, and include amounts from a dividend equivalent feature. Following the award, he holds 33,090.8600 stock units and 1351.0000 common shares directly.
Dimensional Fund Advisors LP, a Delaware limited partnership and registered investment adviser, reported beneficial ownership for Section 13(d) purposes of 2,857,738 shares of HB Fuller Co common stock, representing 5.3% of the class. Dimensional has sole voting power over 2,801,035 shares and sole dispositive power over 2,857,738 shares, with no shared voting or dispositive authority. All reported shares are held in client funds and accounts for which Dimensional or its subsidiaries provide investment management or advisory services, and those funds have the right to receive dividends and sale proceeds. Dimensional states that it may be deemed the beneficial owner of these shares through its advisory role but expressly disclaims beneficial ownership other than as may be deemed under Section 13(d) of the Securities Exchange Act of 1934.
FULLER H B CO senior vice president Joao Magalhaes reported a Form 4 showing an option exercise and his equity holdings. He exercised an employee stock option to acquire 1,658 shares of common stock at $50.10 per share, resulting in 5,523 common shares held directly after the transaction. The filing also lists multiple outstanding stock options and restricted stock units over common stock with various exercise prices and expiration dates, many vesting in three annual installments of 33%, 33%, and 34% and converting into common stock on a 1-for-1 basis, with some RSU amounts including dividend equivalent reinvestments.
Corkrean John J reported acquisition or exercise transactions in this Form 4 filing.
H.B. Fuller Executive VP and CFO John J. Corkrean reported a compensation-related award of phantom stock units linked to the company’s common shares. He received 215.85 phantom units at a reference price of $58.39 per unit, each convertible into one share of common stock.
After this grant, Corkrean holds 34,639.58 phantom units in total. The filing also shows direct ownership of 59,508 shares of common stock and multiple outstanding stock option and restricted stock unit awards, reflecting a substantial portion of his compensation tied to H.B. Fuller’s equity performance.
H.B. Fuller senior vice president Heather Campe reported updated equity holdings, including a compensation-related grant of 38.1500 Phantom Units tied to common stock at $58.3900 per unit. After this award, she directly holds 24,653.0782 shares of common stock and 5,776.5400 Phantom Units.
Campe also retains multiple restricted stock units and employee stock options on H.B. Fuller common stock. The options carry exercise prices between $51.8900 and $77.7200 per share with expiration dates ranging from 2028 to 2036. The restricted stock units and Phantom Units generally convert into common shares on a 1-for-1 basis, with some positions benefiting from dividend reinvestment and dividend equivalent features.
H.B. Fuller Company announced a recommended cash offer to acquire UK-based Advanced Medical Solutions Group plc (AMS), valuing AMS at an enterprise value of £715 million. Eligible AMS shareholders will receive £2.85 in cash for each AMS share, via a court-sanctioned scheme of arrangement under UK law.
The deal targets high-growth medical markets and is expected to deliver approximately $55 million (about £41 million) in combined run-rate revenue and cost synergies by 2031, supporting H.B. Fuller’s path to an EBITDA margin above 20%. To fund the transaction and related needs, the company secured a $2,086,713,188 secured bridge credit facility and a $917,000,000 unsecured bridge facility.
The transaction requires AMS shareholder approval, UK court sanction, regulatory clearances and the scheme becoming effective by June 25, 2027, with completion expected by the end of 2026. H.B. Fuller plans to deleverage to a net leverage target of 2.5x to 3x within two years after closing.